Treatment Response to Lycopene in Recurrent Prostate Cancer Confirmed on 18 F-Fluciclovine PET/CT

Chenxi Wu; Charles Marcus; Yoram Baum; Omer Kucuk; David M Schuster

doi:10.1097/RLU.0000000000004547

Treatment Response to Lycopene in Recurrent Prostate Cancer Confirmed on 18 F-Fluciclovine PET/CT

Clin Nucl Med. 2023 Apr 1;48(4):361-363. doi: 10.1097/RLU.0000000000004547. Epub 2023 Jan 14.

Authors

Chenxi Wu¹, Charles Marcus¹, Yoram Baum¹, Omer Kucuk², David M Schuster¹

Affiliations

¹ From the Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University School of Medicine.
² Department of Hematology and Medical Oncology, Emory University School of Medicine, and the Winship Cancer Institute of Emory University, Atlanta, GA.

PMID: 36728146
DOI: 10.1097/RLU.0000000000004547

Abstract

18 F-fluciclovine (Axumin; Blue Earth Diagnostics, Ltd, Oxford, United Kingdom) PET has shown value in detecting biochemical recurrent prostatic cancer. Lycopene, a plant-based carotenoid, is reported to have potential inhibitory effect on prostate cancer, as a complementary treatment. We report a case of biochemically recurrent prostate cancer showing treatment response to lycopene as seen on an 18 F-fluciclovine PET/CT correlating with serum prostate-specific antigen response.

Publication types

Case Reports

MeSH terms

Carboxylic Acids
Cyclobutanes*
Humans
Lycopene
Male
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography
Prostatic Neoplasms*

Substances

fluciclovine F-18
Lycopene
Carboxylic Acids
Cyclobutanes